Fluconazole-resistant candida albicans vulvovaginitis

Obstetrics and Gynecology

Volumn 120, Issue 6, 2012, Pages 1407-1414

  Marchaim, Dror ^a   Lemanek, Leslie ^a   Bheemreddy, Suchitha ^a   Kaye, Keith S ^a   Sobel, Jack D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BORIC ACID; CASPOFUNGIN; CLOTRIMAZOLE; CRYSTAL VIOLET; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS VULVOVAGINITIS; CANDIDIASIS; COMORBIDITY; DEMOGRAPHY; DRUG TOLERABILITY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIAL STATUS; TREATMENT FAILURE; TREATMENT OUTCOME; VULVOVAGINITIS;

ADULT; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; TREATMENT OUTCOME;

EID: 84870199808     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31827307b2     Document Type: Article

References (30)

1. Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985;152:924-35. (Pubitemid 15016406)
2. Sobel JD. Vulvovaginal candidosis. Lancet 2007;369:1961-71. (Pubitemid 46874580)
3. Donders GG, Bellen G, Mendling W. Management of recurrent vulvo-vaginal candidosis as a chronic illness. Gynecol Obstet Invest 2010;70:306-21.
4. Foxman B, Marsh JV, Gillespie B, Sobel JD. Frequency and response to vaginal symptoms among white and African American women: Results of a random digit dialing survey. JWomens Health 1998;7:1167-74.
5. Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004;351:876-83.
6. Sobel JD. Management of patients with recurrent vulvovaginal candidiasis. Drugs 2003;63:1059-66. (Pubitemid 36693689)
7. Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol 2008;199:613.e1-9.
8. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006;55: 1-94.
9. Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 1996;22:726-7. (Pubitemid 26286331)
10. Dorrell L, Edwards A. Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with nonprescribed triazoles. Sex Transm Infect 2002;78:308-9.
11. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J ClinMicrobiol 2005;43:2155-62. (Pubitemid 40656220)
12. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235-47. (Pubitemid 127774263)
13. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39: 1-8.
14. PfallerMA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D; CLSI Subcommittee for Antifungal Susceptibility Testing. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010;13: 180-95.
15. Pfaller MA, Espinel-Ingroff A, Boyken L, Hollis RJ, Kroeger J, Messer SA, et al. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. J Clin Microbiol 2011;49:845-50.
16. Sobel JD, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy P, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: Clinical implications. Antimicrob Agents Chemother 2003;47:34-8. (Pubitemid 36070338)
17. CLSI. Performance standards for antimibrobial susceptibility testing. Nineteenth informational supplement. Approved standard M100-S19. Wayne (PA): Clinical and Laboratory Standards Institute; 2009.
18. Brammer KW, Feczko JM. Single-dose oral fluconazole in the treatment of vaginal candidosis. Ann N Y Acad Sci 1988;544:561-3. (Pubitemid 19259368)
19. Herzog RE, Ansmann FB. Treatment of vaginal candidiasis with fluconazole. Mycoses 1988;32:204-8.
20. Harris AD. Control group selection is an important but neglected issue in studies of antibiotic resistance. Ann Intern Med 2000;132:925. (Pubitemid 30346864)
21. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-casecontrol study design: Addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005;26:346-51. (Pubitemid 40545579)
22. Bulik CC, Sobel JD, Nailor MD. Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction-impact of two decades. Mycoses 2011;54:34-8.
23. Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: Effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis 2009;64:354-6.
24. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: A prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011;55:532-8.
25. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences. Lancet Infect Dis 2002;2:73-85. (Pubitemid 36114141)
26. MacCallum DM, Coste A, Ischer F, Jacobsen MD, Odds FC, Sanglard D. Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. Antimicrob Agents Chemother 2010;54:1476-83.
27. Houang ET, Chappatte O, Byrne D, Macrae PV, Thorpe JE. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother 1990;34:909-10. (Pubitemid 20142425)
28. Marr KA, Rustad TR, Rex JH, White TC. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother 1999;43:1383-6. (Pubitemid 29259330)
29. Danby CS, Boikov D, Rautemaa R, Sobel JD. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to eleven antifungal agents-implications for clinical use. Antimicrob Agents Chemother 2012;56:1403-6.
30. Fan SR, Liu XP. In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis. Mycoses 2011;54:501-5.